ifosfamide has been researched along with Hearing Loss in 5 studies
Hearing Loss: A general term for the complete or partial loss of the ability to hear from one or both ears.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ifosfamide and methotrexate are widely used for the treatment of pediatric osteosarcoma." | 7.80 | Hearing loss during osteosarcoma chemotherapy: when acute ifosfamide toxicity revealed unnoticed methotrexate encephalopathy. ( Bruneau, B; Chappé, C; Gandemer, V; Robert, G; Taque, S, 2014) |
| "Ten children with newly diagnosed medulloblastoma/primitive neuroectodermal tumor of the posterior fossa were treated with total surgical resection, radiation therapy, and ICE chemotherapy regimen with ifosfamide (900 mg/m2, days 1-5), cisplatin (20 mg/m2, days 1-5), and etoposide (60 mg/m2, days 1-5) every 4 weeks for eight cycles." | 7.69 | Combined irradiation and chemotherapy using ifosfamide, cisplatin, and etoposide for children with medulloblastoma/posterior fossa primitive neuroectodermal tumor--results of a pilot study. ( Abe, H; Ikeda, J; Ishii, N; Kato, T; Sawamura, Y; Shirato, H; Tada, M, 1996) |
| "Ifosfamide and methotrexate are widely used for the treatment of pediatric osteosarcoma." | 3.80 | Hearing loss during osteosarcoma chemotherapy: when acute ifosfamide toxicity revealed unnoticed methotrexate encephalopathy. ( Bruneau, B; Chappé, C; Gandemer, V; Robert, G; Taque, S, 2014) |
| "Ten children with newly diagnosed medulloblastoma/primitive neuroectodermal tumor of the posterior fossa were treated with total surgical resection, radiation therapy, and ICE chemotherapy regimen with ifosfamide (900 mg/m2, days 1-5), cisplatin (20 mg/m2, days 1-5), and etoposide (60 mg/m2, days 1-5) every 4 weeks for eight cycles." | 3.69 | Combined irradiation and chemotherapy using ifosfamide, cisplatin, and etoposide for children with medulloblastoma/posterior fossa primitive neuroectodermal tumor--results of a pilot study. ( Abe, H; Ikeda, J; Ishii, N; Kato, T; Sawamura, Y; Shirato, H; Tada, M, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Robert, G | 1 |
| Chappé, C | 1 |
| Taque, S | 1 |
| Bruneau, B | 1 |
| Gandemer, V | 1 |
| Shkalim-Zemer, V | 1 |
| Ash, S | 1 |
| Toledano, H | 1 |
| Kollender, Y | 1 |
| Issakov, J | 1 |
| Yaniv, I | 1 |
| Cohen, IJ | 1 |
| Janeway, KA | 1 |
| Grier, HE | 1 |
| Sawamura, Y | 1 |
| Ikeda, J | 1 |
| Ishii, N | 1 |
| Kato, T | 1 |
| Tada, M | 1 |
| Abe, H | 1 |
| Shirato, H | 1 |
| Urban, C | 1 |
| Benesch, M | 1 |
| Pakisch, B | 1 |
| Lackner, H | 1 |
| Kerbl, R | 1 |
| Schwinger, W | 1 |
| Oberbauer, R | 1 |
1 review available for ifosfamide and Hearing Loss
| Article | Year |
|---|---|
Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects.
Topics: Antidotes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxorubicin; H | 2010 |
1 trial available for ifosfamide and Hearing Loss
| Article | Year |
|---|---|
Synchronous radiochemotherapy in unfavorable brain tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Che | 1998 |
3 other studies available for ifosfamide and Hearing Loss
| Article | Year |
|---|---|
Hearing loss during osteosarcoma chemotherapy: when acute ifosfamide toxicity revealed unnoticed methotrexate encephalopathy.
Topics: Adolescent; Antineoplastic Agents; Bone Neoplasms; Brain; Brain Diseases; Female; Hearing Loss; Huma | 2014 |
Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Combin | 2015 |
Combined irradiation and chemotherapy using ifosfamide, cisplatin, and etoposide for children with medulloblastoma/posterior fossa primitive neuroectodermal tumor--results of a pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Cerebellar Neopla | 1996 |